Clinical Trials Logo

Clinical Trial Summary

This phase I trial studies the side effects and the best dose of pazopanib hydrochloride in treating patients with solid tumors that has spread to other places in the body and usually cannot be cured or controlled with treatment (advanced) or does not respond to treatment (refractory). Pazopanib hydrochloride may prevent the growth of new blood vessels that tumors need to grow. Studying samples of blood in the laboratory from patients receiving pazopanib hydrochloride may help doctors learn more about the effects of the body on the drug. It may also help doctors understand how well patients respond to treatment.


Clinical Trial Description

PRIMARY OBJECTIVES:

I. To assess the feasibility and safety of individualizing pazopanib (pazopanib hydrochloride) monotherapy based upon attained pazopanib plasma concentrations so as to achieve desired target pazopanib plasma concentration in the highest possible fraction of treated patients.

SECONDARY OBJECTIVES:

I. To assess whether patient cytochrome P450 (CYP) or other polymorphisms may correlate with attained pazopanib levels in response to standard pazopanib dosing.

II. To assess whether patient trough pazopanib levels attained 24 hours after initiation of 800 mg daily fasting may predict steady state trough pazopanib levels after 14 days of pazopanib administration.

III. To assess whether patient trough pazopanib levels may correlate with observed pazopanib toxicities.

OUTLINE: This is a dose-escalation study.

Patients receive pazopanib hydrochloride orally (PO) once daily (QD) on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity. Course length can be extended to 56 days at the discretion of the treating physician after 12 courses (1 year) of treatment on study.

After completion of study treatment, patients are followed up for 3 months. ;


Study Design

Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment


Related Conditions & MeSH terms


NCT number NCT02706366
Study type Interventional
Source Mayo Clinic
Contact
Status Active, not recruiting
Phase Phase 1
Start date March 2012

See also
  Status Clinical Trial Phase
Completed NCT02540876 - Ilorasertib in Treating Patients With CDKN2A-deficient Advanced or Metastatic Solid Cancers That Cannot Be Removed by Surgery Phase 1
Suspended NCT04060849 - Nozin in Preventing Respiratory Viral Infections in Patients Undergoing Stem Cell Transplant, PREV-NOSE STUDY Phase 1
Active, not recruiting NCT03834961 - Larotrectinib in Treating Patients With Previously Untreated TRK Fusion Solid Tumors and TRK Fusion Relapsed Acute Leukemia Phase 2
Completed NCT02897375 - Palbociclib With Cisplatin or Carboplatin in Advanced Solid Tumors Phase 1
Completed NCT01017640 - Veliparib With or Without Mitomycin C in Treating Patients With Metastatic, Unresectable, or Recurrent Solid Tumors Phase 1
Recruiting NCT04147494 - Experimental PET Imaging Scans Before Cancer Surgery to Study the Amount of PET Tracer Accumulated in Normal and Cancer Tissues Early Phase 1
Completed NCT03775616 - Financial Navigation Program Intervention in Supporting Patients With Solid Tumors and Their Caregivers N/A
Active, not recruiting NCT03098277 - Movement Tracking Devices to Monitor Physical Activity in Patients Undergoing Chemotherapy N/A
Completed NCT00503854 - Fatigue and Symptom Burden in Low-Risk Cancer Patients Undergoing Treatment for Febrile Neutropenia
Terminated NCT02414724 - Ribociclib and Gemcitabine Hydrochloride in Treating Patients With Advanced Solid Tumors or Lymphoma Phase 1
Active, not recruiting NCT02876068 - Cediranib Maleate and Selumetinib in Treating Patients With Solid Malignancies Phase 1
Active, not recruiting NCT02142803 - TORC1/2 Inhibitor MLN0128 and Bevacizumab in Treating Patients With Recurrent Glioblastoma or Advanced Solid Tumors Phase 1
Completed NCT00085553 - Tipifarnib and Erlotinib Hydrochloride in Treating Patients With Advanced Solid Tumors Phase 1
Active, not recruiting NCT02867592 - Cabozantinib-S-Malate in Treating Younger Patients With Recurrent, Refractory, or Newly Diagnosed Sarcomas, Wilms Tumor, or Other Rare Tumors Phase 2
Recruiting NCT03023202 - UWCCC Molecular Tumor Board Registry
Active, not recruiting NCT01552356 - Pazopanib Hydrochloride in Treating Patients With Advanced or Refractory Solid Tumors Phase 1
Withdrawn NCT02567396 - Talazoparib in Treating Patients With Advanced or Metastatic Solid Tumors That Cannot Be Removed by Surgery and Liver or Kidney Dysfunction Phase 1
Completed NCT02360215 - Memantine Hydrochloride and Whole-Brain Radiotherapy With or Without Hippocampal Avoidance in Reducing Neurocognitive Decline in Patients With Brain Metastases Phase 3
Withdrawn NCT03804255 - Assessment of Current Biomarker Testing Practices for Common Solid Cancers in Precision Oncology in the Community Setting
Completed NCT02646319 - Nanoparticle Albumin-Bound Rapamycin in Treating Patients With Advanced Cancer With mTOR Mutations Early Phase 1